DGIdb - HMGCR Gene Record

HMGCR 3156 Druggable Genome

Alternate Names:

3156
3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE
HMGCR
LDLCQ3
142910
5006
ENSG00000113161
OTTHUMG00000102069
3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE (EC 1.1.1.34) (HMG-COA REDUCTASE). [SOURCE:UNIPROT/SWISSPROT;ACC:P04035]
HMG-CoA reductase
3-hydroxy-3-methylglutaryl-coenzyme A reductase
P04035
HMDH_HUMAN
639
hydroxymethylglutaryl-CoA reductase
PA189
T53585
NM_000859\|NM_001130996
NP_000850\|NP_001124468

Gene Info:

Human Readable Name	DRUGGABLE GENOME
Uniprot Evidence	1: Evidence at protein level
Interpro Short Name	HMG_CoA_Rdtase
Interpro Type	Family
Interpro Name	Hydroxymethylglutaryl-CoA reductase, class I/II
Interpro Acc	IPR002202
Uniprot Status	Swiss-Prot
Target Class	Enzymes
Target Subclass	EC:1.1.1.34
Transmembrane Helix Count	8
Target Subclass	1.1
Target Main Class	Enzymes
Gene Biotype	PROTEIN_CODING
GuideToPharmacology Gene Category Name	Lanosterol biosynthesis pathway
GuideToPharmacology Gene Category ID	104

(9 More Sources)

Gene Categories: Category Details

DRUGGABLE GENOME
ENZYME

Publications:

Baxter et al., Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight., Trends Endocrinol. Metab.
Maejima et al., 2004, Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell., Biochem. Biophys. Res. Commun.
Davidson, 2002, Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia., Expert Opin Investig Drugs
Bösel et al., 2005, Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones., J. Neurochem.
Jafari et al., 2003, Efficacy of alternate-day dosing versus daily dosing of atorvastatin., J. Cardiovasc. Pharmacol. Ther.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Cuevas A et al., 2016, HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals., Basic Clin Pharmacol Toxicol
Thompson JF et al., 2009, Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort., Circ Cardiovasc Genet
Donnelly LA et al., 2008, A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study., Pharmacogenet Genomics
Krauss RM et al., 2008, Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment., Circulation
Polisecki E et al., 2008, Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER., Atherosclerosis
Singer JB et al., 2007, Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients., J Lipid Res
Thompson JF et al., 2005, An association study of 43 SNPs in 16 candidate genes with atorvastatin response., Pharmacogenomics J
Chasman DI et al., 2004, Pharmacogenetic study of statin therapy and cholesterol reduction., JAMA
MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol
Pappu et al., 2003, Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia., J. Lab. Clin. Med.
Kocarek et al., 2002, Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes., Drug Metab. Dispos.
Stoebner et al., 2003, [Simvastatin-induced lichen planus pemphigoides]., Ann Dermatol Venereol
Liu et al., 2003, Determination of simvastatin-derived HMG-CoA reductase inhibitors in biomatrices using an automated enzyme inhibition assay with radioactivity detection., J Pharm Biomed Anal
Cenedella et al., 2003, Discordant expression of the sterol pathway in lens underlies simvastatin-induced cataracts in Chbb: Thom rats., J. Lipid Res.
Carbonell et al., 2005, Binding thermodynamics of statins to HMG-CoA reductase., Biochemistry
Podar et al., 2009, Emerging therapies for multiple myeloma., Expert Opin Emerg Drugs
Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
Buxbaum et al., 2001, Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide., J. Alzheimers Dis.
Farina et al., 2002, Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells., Clin. Exp. Metastasis
Baranova et al., 2002, [Concentration on Diapak C 16 capsules of lovastatin, mevinolinic acid and other inhibitors of biosynthesis of sterins produced by Penicillium citrinum 89]., Antibiot. Khimioter.
Abe et al., 2002, Molecular cloning and characterization of an ML-236B (compactin) biosynthetic gene cluster in Penicillium citrinum., Mol. Genet. Genomics
Miyazaki et al., 2002, Effects of pravastatin sodium on mevalonate metabolism in common marmosets., J. Biochem.
Dimitroulakos et al., Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas., Neoplasia
Zhou X et al., 2014, Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase., Bioorg Med Chem
McTaggart et al., 2001, Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor., Am. J. Cardiol.
Hanefeld, Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor., Int. J. Clin. Pract.
Chapman et al., 2003, New dimension of statin action on ApoB atherogenicity., Clin Cardiol
Olsson et al., 2002, Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor., Cardiovasc Drug Rev
Davidson, 2002, Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia., Expert Opin Investig Drugs
Holdgate et al., 2003, Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin., Biochem. Soc. Trans.
Ray SK et al., 2000, Atorvastatin: in the management of hyperlipidaemia., J Postgrad Med
Ye YC et al., 2015, Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patients., Chin Med J (Engl)
Morgan et al., 2012, Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects., J. Cardiovasc. Pharmacol.
Hoy SM, 2017, Pitavastatin: A Review in Hypercholesterolemia., Am J Cardiovasc Drugs
Shiomi et al., 1999, Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits., Br. J. Pharmacol.
Blumenthal, 2000, Statins: effective antiatherosclerotic therapy., Am. Heart J.
Denoyelle et al., 2001, Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study., Carcinogenesis
Wong et al., 2001, Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin., Clin. Cancer Res.
Ganné et al., 2000, Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes--a possible protective mechanism against atherothrombosis., Thromb. Haemost.

MEVASTATIN HMGCR

Interaction Score: 6.38

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Competitive

Endogenous Drug? False

Direct Interaction? True

PMIDs:
12518039 12677170 12852453 12671581 10592235 11752352 12433810

Sources:
GuideToPharmacology
CERIVASTATIN HMGCR

Interaction Score: 6.38

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Details of the Assay for Interaction Inhibition of HMG-CoA reductase

Specific Action of the Ligand Competitive

Endogenous Drug? False

PMIDs:
10193776 10740137 11470741 11448925 11752352 11057870

Sources:
GuideToPharmacology TTD
CRILVASTATIN HMGCR

Interaction Score: 3.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
PRAVASTATIN SODIUM HMGCR

Interaction Score: 3.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction HMG-CoA reductase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
TOCOTRIENOL HMGCR

Interaction Score: 3.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
PITAVASTATIN HMGCR

Interaction Score: 3.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name pitavastatin , NK-104,Livalo

PMIDs:
22472908 28130659

Sources:
TdgClinicalTrial TEND
FLUVASTATIN SODIUM HMGCR

Interaction Score: 3.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction HMG-CoA reductase inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
ROSUVASTATIN CALCIUM HMGCR

Interaction Score: 3.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction HMG-CoA reductase inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
ROSUVASTATIN HMGCR

Interaction Score: 2.94

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Competitive

Endogenous Drug? False

Direct Interaction? True

PMIDs:
11256847 11501230 12539816 12481202 16128575 11752352 11772327 12773150

Sources:
TdgClinicalTrial TEND GuideToPharmacology TTD
FLUVASTATIN HMGCR

Interaction Score: 2.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name fluvastatin sodium,Lescol and Lescol XL

Details of the Assay for Interaction Inhibition of HMG-CoA reductase

PMIDs:
18815589 18332269 18261733 17563401 16103896 15199031 19249983 11752352 10592235

Sources:
TdgClinicalTrial TEND GuideToPharmacology PharmGKB TTD
LOVASTATIN HMGCR

Interaction Score: 1.71

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name lovastatin,Mevacor, Altocor, Altoprev

Novel drug target Established target

Mechanism of Interaction HMG-CoA reductase inhibitor

PMIDs:
12214063 12405293 19249983 12369143 11752352 12172803 12204108 12082550 24726306 17563401 18815589 18332269 16103896 18261733 15199031

Sources:
DTC TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB TTD
CERIVASTATIN SODIUM HMGCR

Interaction Score: 1.59

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction HMG-CoA reductase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
TERIFLUNOMIDE HMGCR

Interaction Score: 1.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
PITAVASTATIN CALCIUM HMGCR

Interaction Score: 1.59

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction HMG-CoA reductase inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
ATORVASTATIN CALCIUM HMGCR

Interaction Score: 1.59

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction HMG-CoA reductase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PRAVASTATIN HMGCR

Interaction Score: 1.28

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CRES pravastatin

Novel drug target Established target

Trial Name pravastatin and fenofibrate,PravaFen

PMIDs:
11752352 18815589 18332269 18261733 17563401 16103896 15199031 11298482 25591572

Sources:
TdgClinicalTrial TEND GuideToPharmacology PharmGKB TTD
SIMVASTATIN HMGCR

Interaction Score: 1.24

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name HL 007, simvastatin + amlodipine

Novel drug target Established target

Trial Name MK-0542B, extended release niacin + laropiprant +simvastatin

PMIDs:
16680159 18815589 18332269 18261733 17563401 16103896 15199031 12677170 12433810 12671581 11752352 12852453 12518039 16128575

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB TTD
ATORVASTATIN HMGCR

Interaction Score: 1.01

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Details of the Assay for Interaction In vitro inhibition of HMG-CoA reductase

Specific Action of the Ligand Competitive

Endogenous Drug? False

PMIDs:
15109613 15474503 12769127 15748157 12808485 11752352 26408409 20031582 18815589 18332269 18261733 17563401 16103896 15199031

Sources:
TdgClinicalTrial TEND GuideToPharmacology PharmGKB TTD
LAROPIPRANT HMGCR

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
ASPIRIN HMGCR

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD

Ensembl: ENSG00000113161
- Version: 101_38
Alternate Names:

HMGCR Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

RussLampel: ENSG00000113161

Version: 26-July-2011

Alternate Names:

ENSG00000113161 Ensembl Gene Id

HMGCR Display Id

3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE (EC 1.1.1.34) (HMG-COA REDUCTASE). [SOURCE:UNIPROT/SWISSPROT;ACC:P04035] Description

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

TEND: P04035
- Version: 01-August-2011
Alternate Names:

HMDH_HUMAN Uniprot Id

P04035 Uniprot Accession

3156 Entrez Gene Id

Gene Info:

Transmembrane Helix Count 8

Target Subclass 1.1

Target Main Class Enzymes

Publications:
TdgClinicalTrial: P04035
- Version: January-2014
Alternate Names:

HMGCR Gene Symbol

Gene Info:

Target Class Enzymes

Target Subclass EC:1.1.1.34

Publications:
HopkinsGroom: P04035
- Version: 11-September-2012
Alternate Names:

HMDH_HUMAN Uniprot Id

HMGCR Uniprot Gene Name

P04035 Uniprot Accession

Gene Info:

Human Readable Name DRUGGABLE GENOME

Uniprot Evidence 1: Evidence at protein level

Interpro Short Name HMG_CoA_Rdtase

Gene Categories:

DRUGGABLE GENOME

Publications:
GuideToPharmacology: 3156
- Version: 29-September-2020
Alternate Names:

5006 HUGO Gene ID

5006 HUGO Gene Symbol

3-hydroxy-3-methylglutaryl-CoA reductase HUGO Gene Name

Gene Info:

GuideToPharmacology Gene Category Name Lanosterol biosynthesis pathway

GuideToPharmacology Gene Category ID 104

Gene Categories:

ENZYME

Publications:

PharmGKB: HMGCR

Version: 18-August-2020

Alternate Names:

PA189 PharmGKB ID

Gene Info:

Publications:

Singer JB et al., 2007, Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients., J Lipid Res

Donnelly LA et al., 2008, A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study., Pharmacogenet Genomics

Krauss RM et al., 2008, Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment., Circulation

DTC: HMGCR

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol

Zhou X et al., 2014, Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase., Bioorg Med Chem

HingoraniCasas: ENSG00000113161
- Version: 31-May-2017
Alternate Names:

ENSG00000113161 Gene Symbol

HMGCR Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
ChemblInteractions: HMGCR
- Version: chembl_23
Alternate Names:

HMGCR GENE_SYMBOL

3-hydroxy-3-methylglutaryl-coenzyme A reductase UNIPROT

HMG-CoA reductase UNIPROT

Gene Info:

Publications:
TTD: HMG-CoA reductase
- Version: 2020.06.01
Alternate Names:

HMGCR TTD Gene Abbreviation

T53585 TTD Target ID

Gene Info:

Publications:
Pharos: HMGCR
- Version: 01-May-2021
Alternate Names:

3-hydroxy-3-methylglutaryl-coenzyme A reductase Gene Name

P04035 UniProt ID

Gene Info:

Gene Categories:

ENZYME

Publications:
ClearityFoundationClinicalTrial: HMGCR
- Version: 15-June-2013
Alternate Names:

Gene Info:

Publications:

Specific Action of the Ligand	Competitive
Endogenous Drug?	False
Direct Interaction?	True

Details of the Assay for Interaction	Inhibition of HMG-CoA reductase
Specific Action of the Ligand	Competitive
Endogenous Drug?	False

Mechanism of Interaction	HMG-CoA reductase inhibitor
Direct Interaction	yes

Novel drug target	Established target
Trial Name	pitavastatin , NK-104,Livalo

Trial Name	lovastatin,Mevacor, Altocor, Altoprev
Novel drug target	Established target
Mechanism of Interaction	HMG-CoA reductase inhibitor

Trial Name	CRES pravastatin
Novel drug target	Established target
Trial Name	pravastatin and fenofibrate,PravaFen

Trial Name	HL 007, simvastatin + amlodipine
Novel drug target	Established target
Trial Name	MK-0542B, extended release niacin + laropiprant +simvastatin

Details of the Assay for Interaction	In vitro inhibition of HMG-CoA reductase
Specific Action of the Ligand	Competitive
Endogenous Drug?	False

ENSG00000113161	Ensembl Gene Id
HMGCR	Display Id
3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE (EC 1.1.1.34) (HMG-COA REDUCTASE). [SOURCE:UNIPROT/SWISSPROT;ACC:P04035]	Description

HMDH_HUMAN	Uniprot Id
P04035	Uniprot Accession
3156	Entrez Gene Id

5006	HUGO Gene ID
5006	HUGO Gene Symbol
3-hydroxy-3-methylglutaryl-CoA reductase	HUGO Gene Name

HMGCR	GENE_SYMBOL
3-hydroxy-3-methylglutaryl-coenzyme A reductase	UNIPROT
HMG-CoA reductase	UNIPROT

3-hydroxy-3-methylglutaryl-coenzyme A reductase	Gene Name
P04035	UniProt ID

HMGCR Gene Record

HMGCR 3156 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Competitive Endogenous Drug? False Direct Interaction? True

PMIDs: 12518039 12677170 12852453 12671581 10592235 11752352 12433810

Sources: GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Details of the Assay for Interaction Inhibition of HMG-CoA reductase Specific Action of the Ligand Competitive Endogenous Drug? False

PMIDs: 10193776 10740137 11470741 11448925 11752352 11057870

Sources: GuideToPharmacology TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction HMG-CoA reductase inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name pitavastatin , NK-104,Livalo

PMIDs: 22472908 28130659

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction HMG-CoA reductase inhibitor

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction HMG-CoA reductase inhibitor

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Competitive Endogenous Drug? False Direct Interaction? True

PMIDs: 11256847 11501230 12539816 12481202 16128575 11752352 11772327 12773150

Sources: TdgClinicalTrial TEND GuideToPharmacology TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name fluvastatin sodium,Lescol and Lescol XL Details of the Assay for Interaction Inhibition of HMG-CoA reductase

PMIDs: 18815589 18332269 18261733 17563401 16103896 15199031 19249983 11752352 10592235

Sources: TdgClinicalTrial TEND GuideToPharmacology PharmGKB TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name lovastatin,Mevacor, Altocor, Altoprev Novel drug target Established target Mechanism of Interaction HMG-CoA reductase inhibitor

PMIDs: 12214063 12405293 19249983 12369143 11752352 12172803 12204108 12082550 24726306 17563401 18815589 18332269 16103896 18261733 15199031

Sources: DTC TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction HMG-CoA reductase inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction HMG-CoA reductase inhibitor

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction HMG-CoA reductase inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name CRES pravastatin Novel drug target Established target Trial Name pravastatin and fenofibrate,PravaFen

PMIDs: 11752352 18815589 18332269 18261733 17563401 16103896 15199031 11298482 25591572

Sources: TdgClinicalTrial TEND GuideToPharmacology PharmGKB TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name HL 007, simvastatin + amlodipine Novel drug target Established target Trial Name MK-0542B, extended release niacin + laropiprant +simvastatin

PMIDs: 16680159 18815589 18332269 18261733 17563401 16103896 15199031 12677170 12433810 12671581 11752352 12852453 12518039 16128575

Sources: DTC TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Details of the Assay for Interaction In vitro inhibition of HMG-CoA reductase Specific Action of the Ligand Competitive Endogenous Drug? False

PMIDs: 15109613 15474503 12769127 15748157 12808485 11752352 26408409 20031582 18815589 18332269 18261733 17563401 16103896 15199031

Sources: TdgClinicalTrial TEND GuideToPharmacology PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Competitive

Endogenous Drug? False

Direct Interaction? True

PMIDs:
12518039 12677170 12852453 12671581 10592235 11752352 12433810

Sources:
GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Details of the Assay for Interaction Inhibition of HMG-CoA reductase

Specific Action of the Ligand Competitive

Endogenous Drug? False

PMIDs:
10193776 10740137 11470741 11448925 11752352 11057870

Sources:
GuideToPharmacology TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction HMG-CoA reductase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name pitavastatin , NK-104,Livalo

PMIDs:
22472908 28130659

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction HMG-CoA reductase inhibitor

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction HMG-CoA reductase inhibitor

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Competitive

Endogenous Drug? False

Direct Interaction? True

PMIDs:
11256847 11501230 12539816 12481202 16128575 11752352 11772327 12773150

Sources:
TdgClinicalTrial TEND GuideToPharmacology TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name fluvastatin sodium,Lescol and Lescol XL

Details of the Assay for Interaction Inhibition of HMG-CoA reductase

PMIDs:
18815589 18332269 18261733 17563401 16103896 15199031 19249983 11752352 10592235

Sources:
TdgClinicalTrial TEND GuideToPharmacology PharmGKB TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name lovastatin,Mevacor, Altocor, Altoprev

Novel drug target Established target

Mechanism of Interaction HMG-CoA reductase inhibitor

PMIDs:
12214063 12405293 19249983 12369143 11752352 12172803 12204108 12082550 24726306 17563401 18815589 18332269 16103896 18261733 15199031

Sources:
DTC TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction HMG-CoA reductase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction HMG-CoA reductase inhibitor

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction HMG-CoA reductase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CRES pravastatin

Novel drug target Established target

Trial Name pravastatin and fenofibrate,PravaFen

PMIDs:
11752352 18815589 18332269 18261733 17563401 16103896 15199031 11298482 25591572

Sources:
TdgClinicalTrial TEND GuideToPharmacology PharmGKB TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name HL 007, simvastatin + amlodipine

Novel drug target Established target

Trial Name MK-0542B, extended release niacin + laropiprant +simvastatin

PMIDs:
16680159 18815589 18332269 18261733 17563401 16103896 15199031 12677170 12433810 12671581 11752352 12852453 12518039 16128575

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Details of the Assay for Interaction In vitro inhibition of HMG-CoA reductase

Specific Action of the Ligand Competitive

Endogenous Drug? False

PMIDs:
15109613 15474503 12769127 15748157 12808485 11752352 26408409 20031582 18815589 18332269 18261733 17563401 16103896 15199031

Sources:
TdgClinicalTrial TEND GuideToPharmacology PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Alternate Names:

HMGCR Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Alternate Names:

ENSG00000113161 Ensembl Gene Id

HMGCR Display Id

3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE (EC 1.1.1.34) (HMG-COA REDUCTASE). [SOURCE:UNIPROT/SWISSPROT;ACC:P04035] Description

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME